幽门螺杆菌粪便抗原联合免疫化学法粪便检测的成本效益分析
该研究基于台湾彰化县一项实用性随机临床试验数据,采用马尔可夫决策分析模型模拟队列,评估在两年一次FIT筛查基础上增加一次性幽门螺杆菌粪便抗原检测邀请的终身健康获益与成本。结果显示,联合检测邀请相较单独FIT更具成本效益,在台湾人群中具有成本节约优势,且成本效益受幽门螺杆菌感染率影响显著。
要点
- 在台湾人群中,联合检测邀请相较单独FIT为优势策略,更具效果且成本更低。
- 联合检测的效益成本比为5.08,表明投资回报约为5倍。
- 幽门螺杆菌感染率是成本效益的主要驱动因素,低于21.9%时联合检测超过每QALY 10万美元阈值。
核心结论
- 在依从性不完全的真实世界环境中,邀请联合幽门螺杆菌粪便抗原检测与FIT比单独FIT更具成本效益,在台湾可改善终身结局并节约成本。
研究设计与样本
- 终身成本效益分析,使用马尔可夫决策分析模型模拟基于台湾彰化县实用性随机临床试验的队列,时间跨度为30年,采用社会视角,未来成本和QALYs按3%年贴现率贴现。
主要发现
- 联合检测邀请产生正净货币效益,效益成本比为5.08,表明在台湾人群中投资回报约5倍。
- 从美国成本视角看,联合检测邀请不节约成本,但在试验基线幽门螺杆菌感染率下仍具成本效益。
- 敏感性分析确定幽门螺杆菌感染率为主要驱动因素;当感染率低于21.9%时,联合检测超过每QALY 10万美元阈值。
临床怎么用
- 在幽门螺杆菌感染率中等及以上的地区,可考虑在FIT筛查中联合一次性幽门螺杆菌粪便抗原检测邀请以改善成本效益。
- 决策时需结合当地幽门螺杆菌感染率评估联合检测的成本效益,感染率低于21.9%时需谨慎。
局限性
- 模型基于台湾特定人群和试验数据,外推至其他地区需考虑当地幽门螺杆菌感染率和成本结构差异。
- 从美国成本视角看联合检测不节约成本,成本效益结论受支付意愿阈值影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Helicobacter pylori infection is the leading cause of gastric cancer, yet the economic value of population-based screening and eradication remains uncertain. OBJECTIVE: To project the lifetime health benefits and costs of invitation to 1-time H pylori stool antigen testing added to biennial fecal immunochemical test (FIT) screening compared with FIT alone. DESIGN, SETTING, AND PARTICIPANTS: Lifetime cost-effectiveness analysis conducted using a Markov decision-analytic model to simulate a cohort informed by a pragmatic randomized clinical trial in Changhua County, Taiwan. The model adopted a 30-year time horizon and projected long-term outcomes, including gastric and colorectal cancer mortality, quality-adjusted life-years (QALYs; incorporating both life expectancy and health-related quality of life), and health care expenditures. Costs were evaluated from a societal perspective. One-way and probabilistic sensitivity analyses were performed. Future costs and QALYs were discounted at an annual rate of 3%. EXPOSURES: Helicobacter pylori stool antigen testing plus FIT or FIT alone. MAIN OUTCOMES AND MEASURES: Incremental cost-effectiveness ratio of invitation for H pylori stool antigen testing plus FIT vs FIT alone, measured as the additional cost required to gain 1 QALY per person. Secondary outcomes included net monetary benefit and benefit-cost ratio. RESULTS: Compared with FIT alone, invitation to co-testing was more effective and less expensive (dominant), with a base-case cost-saving incremental cost-effectiveness ratio of $2094 per QALY gained (95% CI, $12 359 saved to $7291 additional cost). This resulted in a positive net monetary benefit, indicating that health benefits exceeded costs, and a benefit-cost ratio of 5.08, indicating an approximately 5-fold return on investment in the Taiwanese population. At a willingness-to-pay threshold of 1 × the Taiwan gross domestic product per QALY ($33 365), invitation to co-testing remained cost-saving in 65.7% of simulations. From a US cost perspective, invitation to co-testing was not cost-saving but remained cost-effective at the trial base-case H pylori prevalence. Sensitivity analyses identified H pylori prevalence as the dominant driver; co-testing exceeded a $100 000-per-QALY threshold when prevalence fell below 21.9%. CONCLUSIONS AND RELEVANCE: In a pragmatic real-world setting with incomplete adherence, invitation to combined H pylori stool antigen testing and FIT was more cost-effective than FIT alone, improving lifetime outcomes and yielding cost savings in Taiwan while remaining cost-effective in higher-cost settings under moderate H pylori prevalence. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01741363.
引用
- Lee YC, Liu JH, Mülder DT, et al. Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen. JAMA. 2026. PMID: 42223961. doi:10.1001/jama.2026.6908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。